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I n t r o d u c t I o n
Patients with multivessel coronary artery disease are common among patients 
presenting with ST elevation myocardial infarction (STEMI). The way to treat the rest 
of the lesions after treating the culprit lesion is not well defined yet. In this article we 
present a patient with inferior STEMI, who had also an ostial left anterior descending 
(LAD) coronary artery stenosis.
c a s e  r e p o r t 
A 43-year-old patient was admitted to the emergency department of our hospital 
due to chest pain from two hours earlier. The patient had hypercholesterolemia treated 
with 20 mg of atorvastatin daily. The electrocardiogram showed ST segment elevation 
in leads II, III, AVF, without right ventricular involvement. The patient was still in pain, 
but clinically stable and his blood pressure was 120/70 mmHg. After receiving loading 
doses of clopidogrel (600 mg), aspirin (325 mg) and unfractionated heparin (5000 IU), 
the patient was transferred to the catheterization laboratory to perform emergency 
coronary angiography and primary PCI. The angiogram showed two-vessel-disease, with 
total occlusion of the right coronary artery in the mid segment (which was the culprit 
lesion) and an ostial 80% stenosis of the LAD. We decided to perform primary PCI 
win the right coronary artery. Intravenous bivalirudin was administered to the patient. 
The transradial approach was chosen by the treating physician. The right coronary 
artery was engaged with a JR4 6F catheter and a soft PCI wire easily penetrated the 
occlusion, establishing TIMI III flow at the distal part of the right coronary artery. Two 
bare metal stents (Liberte 3.0 × 20 mm and Liberte 3.0 × 16 mm) were implanted in 
the mid segment of the right coronary artery with an excellent angiographic result. The 
sheath was withdrawn in the laboratory and a radial compression device (TR band) 
was deployed over the puncture site.
The patient was transferred to the cardiac care unit where he had an uncomplicated 
post infarct recovery. The ultrasound performed showed inferior wall hypokinesia 
with a preserved ejection fraction of 50% and no significant abnormalities from the 
cardiac valves.
Six days after the infarction we decided to proceed with planned PCI of the ostial 
lesion of the LAD. The procedure was performed again from the right radial approach. 
Unfractionated heparin was administered into the sheath. The left coronary artery was 
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engaged with a JL 3.5 6F catheter. After wire crossing of the le-
sion, a direct stenting of the stenosis was performed with a drug 
eluting stent (Promus Element 3.5 × 24 mm), with no residual 
stenosis left. The patient was discharged home the next day. 
d I s c u s s I o n 
We presented a case of inferior STEMI treated with pri-
mary PCI of the culprit lesion at the acute phase and scheduled 
PCI of the ostial LAD lesion before patient discharge, without 
patient having any documented residual angina or pathologi-
cal stress test.
Treatment of patients with multivessel disease presenting 
with STEMI was addressed in the recent ESC guidelines for 
patients with STEMI,1 where an indication of IIa was given to 
culprit lesion only PCI during the primary procedure, with the 
exception of patients with cardiogenic shock or documented 
ischemia.
Recently, the PRAMI trial2 compared preventive PCI for 
all lesions more than 50% during the initial procedure with 
an ischemia-driven staged approach after hospital discharge. 
The study was early discontinued due to ethical reasons, 
because of the obvious superiority of the preventive strategy. 
The primary endpoint of the study, which was the combined 
endpoint of death from cardiac causes, non fatal myocardial 
infarction and refractory angina was met in 21 patients in the 
preventive PCI group and in 53 patients in the non preventive 
PCI group (p<0.001). This was driven mainly by a reduction 
in the refractory angina secondary outcome (12 patients vs 30 
patients, p=0.002), but the other composites of the primary 
endpoint were also significantly reduced (non-fatal myocardial 
infarction: 7 patients vs 20 patients, p=0.009 and cardiac death: 
4 patients vs 10 patients, p=0.07).
This is a very important study because it gives evidence that 
perhaps a more aggressive treatment of patients with STEMI 
and multivessel disease might be beneficial for them. However, 
there are several issues to be discussed. A big percentage of 
patients in PRAMI trial had an inferior STEMI (66% in the 
preventive PCI group and 55% in the non preventive PCI 
group). This may be interpreted that a significant proximal 
LAD stenosis, with prognostic significance, may be left un-
treated in the non preventive PCI arm of the study. Patients 
with STEMI and more than one culprit lesions, who are ap-
proximately 10% of all patients presenting with STEMI, may 
also be a problem in the non preventive PCI group. 
The study also received criticism about its design. The non 
preventive PCI group is normal to have more refractory angina 
reported, since both the patient and the physician knew that the 
patient has untreated significant lesions. The secondary end-
point of non-fatal myocardial infarction may also be affected 
since patients who underwent staged PCI have approximately 
30% possibility of asymptomatic troponin elevation after the 
procedure, a fact that would increase the non-fatal myocardial 
infarction cases in the non preventive PCI group. On the other 
hand, those troponin elevations could not be diagnosed in 
the preventive PCI group, since they would be covered by the 
troponin elevation due to the initial STEMI.
Are any of the arms followed in PRAMI trial according to 
the routine followed in our institution? In the present case we 
followed a strategy different from both arms in the PRAMI 
trial. We performed a staged procedure before hospital dis-
charge and without losing time waiting for angina or ischemia 
documentation. The current policy in our institution is to 
treat the culprit lesion only during primary PCI according to 
the ESC guidelines for patients with STEMI. The treatment 
of the other stenoses is determined by the location and the 
severity of them. Obviously significant proximal LAD stenosis 
are treated before hospital discharge, while significant lesion 
in the right and in the circumflex coronary arteries are treated 
with scheduled PCI two months after STEMI. Patients with-
out angina and borderline lesions, ischemia documentation 
is necessary before a new intervention is decided. The frac-
tional flow reserve could be a reasonable tool distinguishing 
significant from non significant lesions, but the high cost is a 
considerable issue.
c o n c l u s I o n
Treatment of patients with STEMI and multivessel disease 
is challenging and the treatment can be individualized accord-
ing to the lesion severity and location.
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